Advertisement
Singapore markets closed
  • Straits Times Index

    3,224.01
    -27.70 (-0.85%)
     
  • S&P 500

    5,247.61
    -0.88 (-0.02%)
     
  • Dow

    39,784.02
    +23.94 (+0.06%)
     
  • Nasdaq

    16,376.10
    -23.42 (-0.14%)
     
  • Bitcoin USD

    70,778.16
    -224.61 (-0.32%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,958.94
    +26.96 (+0.34%)
     
  • Gold

    2,229.50
    +16.80 (+0.76%)
     
  • Crude Oil

    82.50
    +1.15 (+1.41%)
     
  • 10-Yr Bond

    4.2180
    +0.0220 (+0.52%)
     
  • Nikkei

    40,168.07
    -594.66 (-1.46%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • FTSE Bursa Malaysia

    1,530.60
    -7.82 (-0.51%)
     
  • Jakarta Composite Index

    7,288.81
    -21.28 (-0.29%)
     
  • PSE Index

    6,903.53
    +5.36 (+0.08%)
     

Understanding Nektar Therapeutics’ Operational Performance

Understanding Nektar Therapeutics’ Operational Performance

How Is Nektar Therapeutics Positioned in August? Nektar Therapeutics expects an increase in its general and administrative expenses in 2018 compared to 2017 due to higher noncash stock-based compensation expenses. Nektar Therapeutics saw an operating income of -$50.66 million in the second quarter of 2017 compared to its operating income of $973.6 million in the second quarter of 2018.